Loading...

CNTX CONTEXT THERAPEUTICS INC Investments/Divestments 8-K Filing

CNTX

CNTX

CONTEXT THERAPEUTICS INC

(CNTX)

2024 8-K

Summary

Summary

Nasdaq Extension Granted

Reverse Stock Split

Investor Meetings

Clinical Trial Update

Nasdaq Notification

Clinical Trial Update

License Agreement

Board Appointments

Annual Meeting of Stockholders

Private Placement

FDA IND Application Submission

Bylaws Amendment

Amendment of Collaboration ...

Press Release and Corporate...

Regulation FD Disclosure

Compliance with Minimum Bid...

Annual Meeting of Stockholders

Financial Results and Disco...

Regulation FD Disclosure

Press Release and Corporate...

External Links:

Context Therapeutics Inc. has entered into an asset purchase agreement to acquire CT-95, a bispecific antibody, from Link Immunotherapeutics Inc. for $3.75 million, and plans to initiate a Phase 1 trial in 2025.

AI Assistant

CONTEXT THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.